c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer

Next Previous
Trial Profile

c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms c-TRAK-TN

    • Most Recent Events

    • 26 Jan 2018 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
    • 26 Jan 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.
    • 11 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top